Submit Deal

VITAERIS INC

Summary

Vitaeris is a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection.

Deals Overview

Total Deals1

Valued Deals0

Total Value-

Avg. Deal Size-

Market Context

Senior Management

Kevin Chow
President and CEO

Sort

simpson thacher & bartlett

HQ - New York

legal advisors (1)

1 Shared Deal

1 Opposite

n/a

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy